ARTES links with Indonesian firm for vaccine development

Germany’s ARTES Biotechnology and Indonesia’s Bio Farma have joined forces for the development and manufacturing of vaccine candidates, aiming to capitalize on the strengths of both partners, and signing a first agreement on VLP-based vaccine technology transfer.

ARTES is specialized in cell line and process development, VLP based vaccines as well as in technology transfer for pharmaceutically relevant production processes whereas Bio Farma is involved in the manufacturing of vaccines, serum and other biological products for the Indonesian domestic and international markets.

“Bio Farma is a strong and reliable pharmaceutical partner and the only vaccine and antisera producer for humans in Indonesia. We are more than confident, that we along with Bio Farma will develop vaccines highly relevant for the Indonesian and neighboring markets. We expect that especially developments based on our Metavax technology will contribute to Bio Farma´s vaccine portfolio,” Michael Piontek, founder and managing director of ARTES Biotechnology.